The use of cannabis-based medicines, including THC (tetrahydrocannabinol), for managing chronic neuropathic pain has garnered significant interest. A comprehensive review by the Cochrane Collaboration analyzed 16 studies involving 1,750 participants and found that cannabis-based medicines were more effective than placebo in reducing pain intensity, sleep disturbances, and psychological distress. However, the evidence quality ranged from very low to moderate, and the potential benefits might be outweighed by adverse effects such as dizziness, sleepiness, and mental confusion.

Specifically regarding topical applications, a case series suggested that topical cannabinoids might be beneficial for patients with chemotherapy-induced peripheral neuropathy. While this indicates potential, the evidence is preliminary, and more rigorous studies are needed to confirm efficacy and safety.

Conversely, a study highlighted in Clinical Pain Advisor reported no significant pain-relieving effects from combined CBD (cannabidiol) and THC treatments in patients with peripheral neuropathic pain who had prior treatments. This underscores the variability in patient responses and the necessity for further research to identify which subgroups might benefit from such therapies.

While some studies suggest that THC-containing products, including topicals, may offer relief for neuropathic pain, the current evidence is mixed and of varying quality. Potential benefits must be carefully weighed against possible adverse effects. High-quality, long-term randomized controlled trials focusing on topical THC applications are essential to determine their efficacy and safety in neuropathic pain management. 

“Sweet Relief is a cream on the market with the highest THC content. People with neuropathy have found it beneficial.”

You may also be interested in reading THC Cream for Pain Relief: A Promising Approach for Neuropathy.Sources: